Current studentsExisting staffContact us
 

CoVaccine HT™ adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1

Simple item page
dc.contributor.authorLakhan, N.
dc.contributor.authorStevens, N.
dc.contributor.authorDiener, K.
dc.contributor.authorHayball, J.
dc.date.issued2016
dc.description.abstractAdjuvants are used to enhance the immune response against specific antigens for the production of antibodies, with the choice of adjuvant most critical for poorly immunogenic and self-antigens. This study quantitatively and qualitatively evaluated CoVaccine HT™ and Freund's adjuvants for eliciting therapeutic ovine polyclonal antibodies targeting the endogenous alarmin, high mobility group box-1 (HMGB1). Sheep were immunised with HMGB1 protein in CoVaccine HT™ or Freund's adjuvants, with injection site reactions and antibody titres periodically assessed. The binding affinity of antibodies for HMGB1 and their neutralisation activity was determined in-vitro, with in vivo activity confirmed using a murine model of endotoxemia. Results indicated that CoVaccine HT™ elicited significantly higher antibody tires with stronger affinity and more functional potency than antibodies induced with Freund's adjuvants. These studies provide evidence that CoVaccine HT™ is superior to Freund's adjuvants for the production of antibodies to antigens with low immunogenicity and supports the use of this alternative adjuvant for clinical and experimental use antibodies.
dc.identifier.citationJournal of Immunological Methods, 2016; 439:37-43
dc.identifier.doi10.1016/j.jim.2016.09.008
dc.identifier.issn0022-1759
dc.identifier.issn1872-7905
dc.identifier.orcidDiener, K. [0000-0001-8417-5542]
dc.identifier.orcidHayball, J. [0000-0002-3089-4506]
dc.identifier.urihttps://hdl.handle.net/11541.2/122524
dc.language.isoen
dc.publisherELSEVIER SCIENCE BV
dc.rightsCopyright 2016 Elsevier B.V. Access Condition Notes: Postprint available after 1 October 2017
dc.source.urihttp://dx.doi.org/10.1016/j.jim.2016.09.008
dc.subjectAnimals
dc.subjectMice, Inbred C57BL
dc.subjectSheep, Domestic
dc.subjectEndotoxemia
dc.subjectDisease Models, Animal
dc.subjectLipopolysaccharides
dc.subjectHMGB1 Protein
dc.subjectAdjuvants, Immunologic
dc.subjectFreund's Adjuvant
dc.subjectImmunization
dc.subjectAntibody Affinity
dc.subjectTime Factors
dc.subjectAntibodies, Neutralizing
dc.titleCoVaccine HT™ adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1
dc.typeJournal article
pubs.publication-statusPublished
ror.fileinfo12196858140001831 13196858130001831 9916100602401831_Postprint
ror.mmsid9916100602401831

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
9916100602401831_12196858140001831_9916100602401831_12147848310001831_13147848300001831_CS.pdf
Size:
723.92 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download

Collections